NASDAQ:MORF

Morphic Stock Forecast, Price & News

$55.08
-0.32 (-0.58 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$52.70
Now: $55.08
$56.62
50-Day Range
$32.85
MA: $61.92
$84.85
52-Week Range
$12.09
Now: $55.08
$93.00
Volume78,913 shs
Average Volume402,158 shs
Market Capitalization$1.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.01
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4Ã7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and MORF-720 and MORF-627, which is in the preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avÃ1 for the treatment of fibrotic diseases, and avÃ8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MORF
CUSIPN/A
CIKN/A
Phone781-996-0955
Employees89
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.98 million
Book Value$4.62 per share

Profitability

Net Income$-43,330,000.00

Miscellaneous

Market Cap$1.79 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable

Headlines

Morphic Holding, Inc. (NASDAQ:MORF) Short Interest Update
April 17, 2021 |  americanbankingnews.com
Is Morphic Holding a Buy?
April 14, 2021 |  finance.yahoo.com
Why Morphic Holding Stock Is Falling Today
March 2, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.29 out of 5 stars

Medical Sector

821st out of 2,024 stocks

Pharmaceutical Preparations Industry

390th out of 772 stocks

Analyst Opinion: 2.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$55.08
-0.32 (-0.58 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MORF News and Ratings via Email

Sign-up to receive the latest news and ratings for MORF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Morphic (NASDAQ:MORF) Frequently Asked Questions

Is Morphic a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Morphic stock.
View analyst ratings for Morphic
or view top-rated stocks.

What stocks does MarketBeat like better than Morphic?

Wall Street analysts have given Morphic a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Morphic wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Morphic?

Morphic saw a decrease in short interest in March. As of March 31st, there was short interest totaling 604,700 shares, a decrease of 29.3% from the March 15th total of 854,900 shares. Based on an average daily trading volume, of 423,000 shares, the short-interest ratio is currently 1.4 days. Currently, 3.5% of the company's shares are sold short.
View Morphic's Short Interest
.

When is Morphic's next earnings date?

Morphic is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Morphic
.

How were Morphic's earnings last quarter?

Morphic Holding, Inc. (NASDAQ:MORF) posted its earnings results on Sunday, February, 28th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.07. The firm earned $5.90 million during the quarter, compared to analyst estimates of $8 million.
View Morphic's earnings history
.

How has Morphic's stock price been impacted by Coronavirus?

Morphic's stock was trading at $14.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MORF shares have increased by 282.2% and is now trading at $55.08.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MORF?

2 brokers have issued 12 month target prices for Morphic's shares. Their forecasts range from $37.00 to $103.00. On average, they expect Morphic's stock price to reach $63.33 in the next twelve months. This suggests a possible upside of 15.0% from the stock's current price.
View analysts' price targets for Morphic
or view top-rated stocks among Wall Street analysts.

Who are Morphic's key executives?

Morphic's management team includes the following people:
  • Dr. Praveen P. Tipirneni M.D., CEO, Pres & Director (Age 53, Pay $788.23k)
  • Dr. Timothy A. Springer Ph.D., Founder, Independent Director & Member of Scientific Advisory Board (Age 73, Pay $50.83k)
  • Dr. Bruce N. Rogers, Chief Scientific Officer (Age 52, Pay $528.71k)
  • Mr. William D. DeVaul Esq., Gen. Counsel & Sec. (Age 50, Pay $490.88k)
  • Dr. Marc Schegerin M.B.A., M.D., CFO & COO (Age 45)
  • Mr. Robert E. Farrell Jr., CPA, CPA, Sr. VP of Fin./Operations & Chief Accounting Officer (Age 56)
  • Mr. Blaise Lippa, Sr. VP of Molecular Discovery
  • Mr. Adrian S. Ray Ph.D., Sr. VP and Head of Biology & Translation
  • Dr. Peter G. Linde M.D., Chief Medical Officer (Age 54)

Who are some of Morphic's key competitors?

What other stocks do shareholders of Morphic own?

When did Morphic IPO?

(MORF) raised $75 million in an initial public offering on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.

What is Morphic's stock symbol?

Morphic trades on the NASDAQ under the ticker symbol "MORF."

How do I buy shares of Morphic?

Shares of MORF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Morphic's stock price today?

One share of MORF stock can currently be purchased for approximately $55.08.

How much money does Morphic make?

Morphic has a market capitalization of $1.79 billion and generates $16.98 million in revenue each year. The company earns $-43,330,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis.

How many employees does Morphic have?

Morphic employs 89 workers across the globe.

What is Morphic's official website?

The official website for Morphic is www.morphictx.com.

Where are Morphic's headquarters?

Morphic is headquartered at 35 Gatehouse Drive A2, Waltham MA, 02451.

How can I contact Morphic?

Morphic's mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The company can be reached via phone at 781-996-0955.


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.